Imugene expands CAR T-Cell and Oncolytic Virotherapy trials in Australia and the US

Proactive - Interviews for investors

Imugene Ltd (ASX:IMU, OTC:IUGNF) managing director and CEO Leslie Chong joins Proactive’s Tylah Tully to provide a company update, including launching the first Australian site for the Phase 1b clinical trial of its azer-cel (azercabtagene zapreleucel) allogeneic CAR T-cell therapy. The Royal Prince Alfred Hospital in Sydney will lead Australian patient recruitment, with enrolment beginning in November 2024, marking Australia’s only active trial for allogeneic CAR T-cell therapy in treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This Australian expansion offers patients access to azer-cel, addressing critical treatment gaps for DLBCL, an aggressive form of non-Hodgkin’s lymphoma. Chong emphasised the importance of local access to this innovative therapy. Imugene’s US trials have shown promising results, with three patients achieving complete responses, two of whom received a combination of azer-cel with lymphodepletion and interleukin-2 (IL-2), showing durable responses extending beyond 90 and 120 days. The company has also dosed the first patient in the intratumoural (IT) injection combination arm of its OASIS Phase 1 clinical trial for onCARlytics (CF33-CD19). This trial aims to test the efficacy and safety of Imugene's CD19-expressing oncolytic virotherapy in advanced or metastatic solid tumours. The first colorectal cancer patient was treated at Northwestern University, and the trial is expected to enrol up to 40 participants with various advanced cancers. #ProactiveInvestors #Imugene #ASX #Oncology #CAR_TCellTherapy #AzerCel #Vaxinia #ClinicalTrials #CancerResearch #Immunotherapy #DLBCL #HER2 #BileCancer #Biotechnology #ASX #FDAApproval #OrphanDrug #FastTrack #BiotechInvesting #OncolyticVirotherapy #CancerTreatment #CashPosition